Advertisement

Topics

Herpes Simplex Infections - Pipeline Review, H1 2015

01:13 EDT 15 Apr 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Herpes Simplex Infections - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-03-10. This 188-page report is available in PDF from $2000.

Herpes Simplex Infections - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Herpes Simplex Infections - Pipeline Review, H1 2015’, provides an overview of the Herpes Simplex Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Herpes Simplex Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Herpes Simplex Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Herpes Simplex Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Herpes Simplex Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Herpes Simplex Infections Overview 9
Therapeutics Development 10
Pipeline Products for Herpes Simplex Infections - Overview 10
Pipeline Products for Herpes Simplex Infections - Comparative Analysis 11
Herpes Simplex Infections - Therapeutics under Development by Companies 12
Herpes Simplex Infections - Therapeutics under Investigation by Universities/Institutes 16
Herpes Simplex Infections - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Herpes Simplex Infections - Products under Development by Companies 20
Herpes Simplex Infections - Products under Investigation by Universities/Institutes 24
Herpes Simplex Infections - Companies Involved in Therapeutics Development 25
3-V Biosciences, Inc. 25
Adamis Pharmaceuticals Corporation 26
Admedus Ltd 27
Agenus, Inc. 28
AiCuris GmbH & Co. KG 29
AlphaVax, Inc. 30
Astellas Pharma Inc. 31
Beech Tree Labs, Inc. 32
BioApex, s.r.o. 33
CEL-SCI Corporation 34
Chimerix, Inc. 35
Colby Pharmaceutical Company 36
Epiphany Biosciences, Inc. 37
Foamix Pharmaceuticals Ltd. 38
Genocea Biosciences, Inc. 39
GenVec, Inc. 40
Immune Design Corp. 41
Immunovaccine, Inc. 42
Kala Pharmaceuticals, Inc. 43
Mymetics Corporation 44
NanoBio Corporation 45
NanoViricides, Inc. 46
NovaBay Pharmaceuticals, Inc. 47
Onxeo SA 48
Oryzon Genomics S.A. 49
Osel Inc. 50
PaxVax 51
Peregrine Pharmaceuticals, Inc. 52
Profectus BioSciences, Inc. 53
Romark Laboratories, L.C. 54
Sanofi 55
Sanofi Pasteur SA 56
Spider Biotech 57
Starpharma Holdings Limited 58
Vaccibody AS 59
Vaxart, Inc. 60
Vical Incorporated 61
Vironova AB 62
ViroStatics, srl 63
Herpes Simplex Infections - Therapeutics Assessment 64
Assessment by Monotherapy Products 64
Assessment by Combination Products 65
Assessment by Target 66
Assessment by Mechanism of Action 68
Assessment by Route of Administration 70
Assessment by Molecule Type 72
Drug Profiles 74
(celecoxib + famciclovir) - Drug Profile 74
acyclovir - Drug Profile 75
acyclovir - Drug Profile 76
acyclovir - Drug Profile 77
amenamevir - Drug Profile 78
Aspidasept - Drug Profile 79
astodrimer - Drug Profile 80
BA-368 - Drug Profile 82
Biologic for Infectious Disease - Drug Profile 83
brincidofovir - Drug Profile 84
BTL-TMLHSV - Drug Profile 86
C-31G - Drug Profile 87
CEL-1000 - Drug Profile 89
G-103 - Drug Profile 91
GEN-002 - Drug Profile 92
GEN-003 - Drug Profile 93
genital herpes vaccine - Drug Profile 95
genital herpes vaccine [HSV-2] - Drug Profile 96
GV-2207 - Drug Profile 97
HerpeCide-I - Drug Profile 98
herpes [Type-2] vaccine - Drug Profile 99 For more information open Herpes Simplex Infections - Pipeline Review, H1 2015.

SKU: GMDHC6255IDB

Original Article: Herpes Simplex Infections - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Herpes Simplex Infections - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...